Novo Nordisk to Cut US List Prices of Wegovy, Ozempic by Up to 50%

Novo Nordisk will cut US list prices of its diabetes and obesity drugs Wegovy and Ozempic by up to 50% from January, reflecting intensifying GLP-1 market competition and aligning with Medicare price reforms.